Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better healthOUR PORTFOLIO IN STROKE TREATMENTAND PREVENTION[ actilyse® ] [ aggrenox® ] [ pradaxa® ]F.A.S.T.The F.A.S.T (Face, Arms, Speech,Time) algorithm is a quick methodfor assessment of a potential stroke:• Asymmetry of the face – facialdroop on one side• Weakness on one side of thebody – typically, unable to raiseboth arms in parallel• Slurred speech – or inability tounderstand or formulate speech• Other problems, includingconfusion, visual disturbance,dizziness etc.the onset of symptoms to potentialtreatment.Secondary prevention of strokeSurvivors of a transient ischaemic attackor stroke have an increased risk ofanother stroke, which is a major sourceof increased mortality and morbidity.AGGRENOX®aggrenox®/asasantin®retard (extendedreleased dipyridamole + acetylsalicylic acid (ASA)) is indicated to reducethe risk of secondary stroke in patientswho have had a TIA or completedischaemic stroke due to thrombosis.PROFESS®, the world’s largest trial inrecurrent stroke prevention, includedmore than 20,000 patients. The studycompared aggrenox® with clopidogrel,while also analysing whether telmisartan,on top of other standardtherapy, would further reduce the riskof recurrent stroke when comparedwith placebo. In the two antiplateletregimens, the patients had a comparablerisk for stroke as well as for myocardialinfarction or vascular death.QUICK INITIATIVETo improve the efficiency of thestroke patient management process,the quick project is dividedinto four major phases for eachparticipating hospital.ReassessmentCheck upof the strokeunitsImplementationof the actionplanDevelopmentof actionplanTrials in stroke preventionThe prevention of stroke was speci ficallyinvestigated in PROFESS® andstroke was also included in the primaryendpoint of ONTARGET andTRANSCEND®.Analysis on structure andtime managementStakeholders todecide on actionsReduce door-toneedletimeEnsurecontinuityCardiovascular diseases69